FRANKFURT (Reuters) – German drugmaker Bayer expects the world’s largest economies to pool billions of euros in funding for the development of antibiotics against the growing threat of drug-resistant superbugs, its chief executive said on Friday.
“I expect a multinational fund for antibiotics research. One country alone can’t shoulder it,” CEO Marijn Dekkers told Germany’s Der Spiegel magazine, according to an excerpt of an interview provided to Reuters on Friday.
FRANKFURT, May 19 (Reuters) – Merck KGaA said the
recent takeover of high-tech chemicals maker AZ Electronic
Materials and a strong U.S. dollar will help it overcome a drop
in revenue from its best-selling drug, multiple sclerosis
treatment Rebif, this year.
The German diversified chemicals and healthcare group on
Tuesday forecast adjusted earnings before interest, taxes,
depreciation and amortisation (EBITDA) of 3.45-3.55 billion
euros ($3.9-4.0 billion) in 2015, up from 3.39 billion last
FRANKFURT, May 15 (Reuters) – German drugs and chemicals
group Bayer believes further consolidation in the
crop chemicals and seeds markets, is likely regardless of the
outcome of Monsanto’s bid for Syngenta.
“It remains to be seen when, in what form and with which
partners the consolidation will advance,” Bayer CropScience
Chief Executive Liam Condon said in an emailed response to
questions from Reuters.
FRANKFURT, April 30 (Reuters) – Germany’s BASF
expects a slide in earnings at its Wintershall oil and gas unit
brought on by lower oil prices to cancel out gains at its basic
petrochemicals and crop protection businesses this year.
Crude oil prices have recovered from a six-year low reached
earlier this year, but average prices over the first quarter
were more than 45 percent below year-earlier levels.
FRANKFURT, April 30 (Reuters) – German drugmaker Bayer
said strong overseas currencies allowed it to lift
its full-year earnings and sales targets, adding to revenue
growth from newly launched drugs.
Sales are now seen at roughly 48-49 billion euros ($53-$54
billion) this year, up from a previous goal of about 46 billion
euro, with currency effects giving a boost of about 9 percent,
more than the 3 percent previously expected.
FRANKFURT, April 29 (Reuters) – German healthcare group
Fresenius SE lifted its full-year earnings forecast as
its rivals in the U.S. generic infusion drug market grappled
with supply shortages longer than expected.
For 2015, Fresenius now expects adjusted net income growth
of 13 percent to 16 percent, adjusted for currency swings, up
from a previous outlook for currency-adjusted growth of 9
percent to 12 percent.
FRANKFURT (Reuters) – If customers of Germany’s Harting Group, a maker of industrial plugs and sockets, want bespoke products, they can buy them — if they’re prepared to assemble them from a kit themselves.
Volker Franke, the head of Harting’s assembly systems and machine tools business, is working hard to change that. His team is developing an automated production line that takes orders online and makes plugs to a customer’s individual specification.
FRANKFURT, April 1 (Reuters) – Roche, the world’s
largest cancer drugmaker, is ready to collaborate with rivals to
find new combination therapies for multi-pronged treatments, its
chief executive said.
Severin Schwan said the company was investing very heavily in
a new wave of cancer immunotherapy drugs, where finding
combination therapies to attack tumours on different fronts
would be “extremely important”.
FRANKFURT, March 26 (Reuters) – Germany’s Evonik
has been evaluating Clariant and other speciality
chemicals companies for a potential takeover bid, sources told
Reuters, adding that it had yet to decide how to proceed.
The Financial Times reported on Thursday that Evonik was
considering a bid for Swiss peer Clariant to create a group with
a market value of more than 20 billion euros ($22 billion), but
several sources familiar with the situation said it had also
looked at DSM and Croda.
FRANKFURT (Reuters) – Germany’s Bayer said it was considering strategic options for its home and garden consumer products business, maker of Baby Bio plant feed, as its crop protection arm focuses on professional customers.
People familiar with the matter told Reuters that Bayer was preparing to sell the business and was gauging the interest of prospective buyers, which could be private equity or industry players. The business generated 220 million euros ($236 million) in annual sales last year.